ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 730

Cell-Mediated Immune Responses To Influenza and Herpesvirus Antigen Stimulation Are Conserved But Adversely Impacted By Immunosuppressive Therapy and Active Infection In Patients With Granulomatosis With Polyangiitis

John McKinnon1, Robbie Mailliard2, Dawn McClemens-McBride3, Donald Jones3, Charles Rinaldo Jr.4 and Kathleen Maksimowicz-McKinnon5, 1Infectious Disease, Henry Ford Hospital, Detroit, MI, 2Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, 3Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Infectious Diseases and Microbiology, Pathology, University of Pittsburgh, Pittsburgh, PA, 5Rheumatology, Henry Ford Hospital, Detroit, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: immune response, Infection, vasculitis and viruses

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Reactivation of chronic herpesvirus infections is not uncommon in immunosuppressed patients, including those with granulomatosis with polyangiitis (GPA).  The effects of GPA disease and therapy on cell-mediated immunity against herpesviruses are not well established.   Although immunosuppressive therapy is clearly associated with viral reactivation disease, data from other cohorts demonstrate that altered immunocompetence from other infections may also be an important contributing factor. We examined the effects of recent and acute infections on cell-mediated immune response against influenza and herpesvirus antigens in a well-characterized cohort of patients with GPA.

Methods: Twenty GPA patients (mean age: 56 years; 55% female; 100% Caucasian) and 5 age-, race-, and gender-matched healthy controls were prospectively enrolled. Disease features, medications, current and recent infection data, and disease activity scores were obtained. Extended ELISPOTs for interferon-gamma (IFNg) production to CEF and VZV antigens were assessed.

Results: GPA patients had a median disease duration of 86.8 (54) months, median BVAS of 1.0 and VDI of 2.0. Prednisone was used in 15 (75%) of the patients (median dose: 12.5 mg) and steroid-sparing immunosuppressive agents in 14 (70) %; two patients were not receiving IS therapy. An active infection was identified in 30% of the patients at study entry, and 50% had a recent serious infection within the past year.  GPA patients had a significant decline in IFNg median responses to CEF & VZV antigens with increasing prednisone dose (0mg=450 & 192.1; <11mg= 161.8, 7.3; 11-60mg= 202.5, 24.2; 1000mg= 22.5, 25.5) (p=0.21, 0.041 respectively) and with the number of immunosuppressive agents used ( none= 457, 192.5; one= 161.3, 129.3;  two or more= 202.5, 18.5) (none vs. one=0.53, 0.8; none vs. two: p=0.095, 0.095 ).  The presence of an active infection at study entry was associated with a decrease in VZV IFNg response (p=0.024). However, prior herpesvirus infection (1 HSV pneumonia, 4 VZV disease) within the past year was associated with higher CEF response (p=0.036) and a trend towards higher VZV responses (p=0.099).

Conclusion: Immunosuppressive therapy and non-viral infections both decrease cell-mediated immune response against herpes viruses, potentially leading to reactivation disease in patients with GPA, as seen in other immunosuppressed populations. Prior herpesvirus infection is associated with increases in both CEF and VZV responses, suggesting a possible “crossover” protective effect against both CMV and VZV reactivation, which could be important when considering the need and timing of prophylactic interventions.  .


Disclosure:

J. McKinnon,
None;

R. Mailliard,
None;

D. McClemens-McBride,
None;

D. Jones,
None;

C. Rinaldo Jr.,
None;

K. Maksimowicz-McKinnon,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cell-mediated-immune-responses-to-influenza-and-herpesvirus-antigen-stimulation-are-conserved-but-adversely-impacted-by-immunosuppressive-therapy-and-active-infection-in-patients-with-granulomatosis-w/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology